Key facts
- MARABio’s last known valuation is $34.1M (Jan 2025).
- It has raised $26.8M; the latest was Later Stage VC ($20.8M) in Jan 2025.
- Notable investors include MAK Capital, AIF, Mesa Verde Venture Partners, Moai Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for MARABio
- ·The full record, as it builds
Funding rounds
No funding rounds for MARABio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MARABio
Provider of maternal autoantibody-related autism testing intended to determine the risk of autism spectrum disorder (ASD). The company develops a precision technology that is capable of identifying an unusual and distinctive cluster of antibodies that are directed against proteins in the developing brain of mothers whose children are diagnosed with ASD, enabling mothers to initiate specific beneficial behavioral therapies much earlier if their children exhibit signs of developmental delay.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2016
- Employees
- 10
- Website
- marabio.com/
- Ownership
- Privately Held (backing)
MARABio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MARABio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MARABio in its N-PORT filings yet. We sweep new filings monthly.